Literature DB >> 21912451

Intestinal inflammation and colorectal cancer: a double-edged sword?

Angelamaria Rizzo1, Francesco Pallone, Giovanni Monteleone, Massimo Claudio Fantini.   

Abstract

Chronic inflammation is thought to be the leading cause of many human cancers including colorectal cancer (CRC). Accordingly, epidemiologic and clinical studies indicate that patients affected by ulcerative colitis and Crohn's disease, the two major forms of inflammatory bowel disease, have an increased risk of developing CRC. In recent years, the role of immune cells and their products have been shown to be pivotal in initiation and progression of colitis-associated CRC. On the other hand, activation of the immune system has been shown to cause dysplastic cell elimination and cancer suppression in other settings. Clinical and experimental data herein reviewed, while confirming chronic inflammation as a risk factor for colon carcinogenesis, do not completely rule out the possibility that under certain conditions the chronic activation of the mucosal immune system might protect from colonic dysplasia.

Entities:  

Keywords:  Colorectal cancer; Cytokines; Immunosurveillance; Inflammation; T cells

Mesh:

Substances:

Year:  2011        PMID: 21912451      PMCID: PMC3158408          DOI: 10.3748/wjg.v17.i26.3092

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  102 in total

1.  Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease.

Authors:  S Müller; J Lory; N Corazza; G M Griffiths; K Z'graggen; L Mazzucchelli; A Kappeler; C Mueller
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

2.  Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.

Authors:  Jong Myun Park; Masaki Terabe; Leon T van den Broeke; Debra D Donaldson; Jay A Berzofsky
Journal:  Int J Cancer       Date:  2005-03-10       Impact factor: 7.396

3.  Anti-interleukin-12 antibody for active Crohn's disease.

Authors:  Peter J Mannon; Ivan J Fuss; Lloyd Mayer; Charles O Elson; William J Sandborn; Daniel Present; Ben Dolin; Nancy Goodman; Catherine Groden; Ronald L Hornung; Martha Quezado; Zhiqiong Yang; Markus F Neurath; Jochen Salfeld; Geertruida M Veldman; Ullrich Schwertschlag; Warren Strober
Journal:  N Engl J Med       Date:  2004-11-11       Impact factor: 91.245

4.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

5.  STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells.

Authors:  Frank Hoentjen; R Balfour Sartor; Michitaka Ozaki; Christian Jobin
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

6.  Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells.

Authors:  G Monteleone; L Biancone; R Marasco; G Morrone; O Marasco; F Luzza; F Pallone
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

7.  Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.

Authors:  S Huang; K Xie; C D Bucana; S E Ullrich; M Bar-Eli
Journal:  Clin Cancer Res       Date:  1996-12       Impact factor: 12.531

8.  IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression.

Authors:  X Xu; X Y Fu; J Plate; A S Chong
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

9.  The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.

Authors:  H Kitamura; K Iwakabe; T Yahata; S Nishimura; A Ohta; Y Ohmi; M Sato; K Takeda; K Okumura; L Van Kaer; T Kawano; M Taniguchi; T Nishimura
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

10.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.

Authors:  Claire L Langrish; Yi Chen; Wendy M Blumenschein; Jeanine Mattson; Beth Basham; Jonathan D Sedgwick; Terrill McClanahan; Robert A Kastelein; Daniel J Cua
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

View more
  48 in total

Review 1.  Orphan Nuclear Receptors in Colorectal Cancer.

Authors:  Michael E Kelly; Helen M Mohan; Alan W Baird; Elizabeth J Ryan; Des C Winter
Journal:  Pathol Oncol Res       Date:  2018-06-28       Impact factor: 3.201

2.  Role of Lymphatic Deficiency in the Pathogenesis and Progression of Inflammatory Bowel Disease to Colorectal Cancer in an Experimental Mouse Model.

Authors:  Sarah K Daley; Marlys H Witte; Jalicia Washington; Michael Bernas; Pawel Kiela; Jennifer Thorn; Nathan Tanoue; J Steven Alexander
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

3.  An integrated approach to identify causal network modules of complex diseases with application to colorectal cancer.

Authors:  Zhenshu Wen; Zhi-Ping Liu; Zhengrong Liu; Yan Zhang; Luonan Chen
Journal:  J Am Med Inform Assoc       Date:  2012-09-11       Impact factor: 4.497

Review 4.  Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.

Authors:  Federica Zoratto; Luigi Rossi; Monica Verrico; Anselmo Papa; Enrico Basso; Angelo Zullo; Luigi Tomao; Adriana Romiti; Giuseppe Lo Russo; Silverio Tomao
Journal:  Tumour Biol       Date:  2014-03-28

5.  Systemic macrophage depletion inhibits Helicobacter bilis-induced proinflammatory cytokine-mediated typhlocolitis and impairs bacterial colonization dynamics in a BALB/c Rag2-/- mouse model of inflammatory bowel disease.

Authors:  Sureshkumar Muthupalani; Zhongming Ge; Yan Feng; Barry Rickman; Melissa Mobley; Amanda McCabe; Nico Van Rooijen; James G Fox
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

6.  Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers.

Authors:  Yi-Fang Han; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

7.  Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis.

Authors:  Keqiang Chen; Mingyong Liu; Ying Liu; Teizo Yoshimura; Wei Shen; Yingying Le; Scott Durum; Wanghua Gong; Chunyan Wang; Ji-Liang Gao; Philip M Murphy; Ji Ming Wang
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 8.  Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers.

Authors:  Graciele Almeida de Oliveira; Robert Y S Cheng; Lisa A Ridnour; Debashree Basudhar; Veena Somasundaram; Daniel W McVicar; Hugo Pequeno Monteiro; David A Wink
Journal:  Antioxid Redox Signal       Date:  2016-10-31       Impact factor: 8.401

9.  Forced treadmill exercise training exacerbates inflammation and causes mortality while voluntary wheel training is protective in a mouse model of colitis.

Authors:  Marc D Cook; Stephen A Martin; Collette Williams; Keith Whitlock; Matthew A Wallig; Brandt D Pence; Jeffrey A Woods
Journal:  Brain Behav Immun       Date:  2013-05-23       Impact factor: 7.217

10.  IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry.

Authors:  Brenna L Seufert; Elizabeth M Poole; John Whitton; Liren Xiao; Karen W Makar; Peter T Campbell; Richard J Kulmacz; John A Baron; Polly A Newcomb; Martha L Slattery; John D Potter; Cornelia M Ulrich
Journal:  Carcinogenesis       Date:  2012-09-22       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.